SkinHealth Systems is a medical-aesthetics platform whose Hydrafacial franchise still prints high-margin consumables even as new device placements keep shrinking. The latest quarter shows that tension in full. Recurring serums and tips still carry most of a $72 million print, yet the placement engine that feeds the install base remains under pressure. Management cut costs hard enough to lift adjusted earnings, but the equity now sits between a near-term convertible maturity and a Nasdaq bid-price vote. The investment debate is whether the annuity can fund that capital-structure cleanup without another shrink in the installed base.
Gross margin recovered because last year's trade-in and inventory charges rolled off, not because demand re-accelerated. Delivery-system sales fell again, with Europe taking the sharpest drop. Consumables still produced $54 million, which is the bull case in miniature: the existing book still buys tips and serums. Adjusted EBITDA rose to $17 million even as sales declined, because personnel costs came out of the run-rate. That mix is attractive only if placements stop falling. A shrinking install base eventually starves the annuity.
Cash at mid-year was $206 million against a current convertible tranche due in October. Management cut full-year sales guidance and still pointed to a weaker third quarter. The remaining questions are simple. Does the install base keep buying consumables after the October cash drain? And does the September reverse-split vote fix the listing without signaling that demand never returns?